Beta Bionics Reports 57% Revenue Growth to $27.6 Million in Latest Quarter

Beta Bionics, Inc. reported significant financial performance improvements in its latest quarterly filing, with net sales reaching $27.6 million for the three months ended March 31, 2026, a 57% increase from $17.6 million in the same period last year. The growth was primarily driven by a rise in sales of single-use products associated with the iLet insulin delivery device, which accounted for 62% of total net sales, up from 43% a year earlier. The company’s gross profit also saw a substantial increase, rising to $16.4 million, representing an 83% year-over-year growth, with gross margins improving to 59% from 51%.

Operating expenses for the quarter increased to $40.7 million, up 47% from $27.6 million in the prior year, largely due to heightened research and development costs, which rose by 36% to $10.4 million, and sales and marketing expenses, which surged by 55% to $20.7 million. The net loss for the quarter was reported at $21.9 million, a 24% improvement compared to a net loss of $28.7 million in the same quarter of 2025. This reduction in losses was attributed to the absence of significant prior-year expenses related to warrant liabilities, which had negatively impacted the previous year's results.

In terms of operational developments, Beta Bionics has focused on expanding its market presence through a multi-channel coverage strategy, which includes both Durable Medical Equipment (DME) and Pharmacy Benefit Plan (PBP) reimbursement channels. The PBP channel accounted for 39% of net sales in the latest quarter, up from 22% a year earlier, reflecting a strategic shift towards broader pharmacy benefit coverage. The company has also reported an increase in its customer base, with approximately 70% of new patient starts coming from individuals previously using multiple daily injections (MDI), indicating a successful transition to the iLet device.

Beta Bionics continues to invest in research and development, with plans to enhance its product offerings, including the development of a patch pump and a bihormonal system that combines insulin and glucagon delivery. The company has also entered into collaboration agreements with Xeris Pharmaceuticals to develop glucagon products for use with the iLet. As of March 31, 2026, Beta Bionics had cash, cash equivalents, and investments totaling $239.5 million, which it expects will be sufficient to fund operations through the first half of 2028.

Looking ahead, Beta Bionics anticipates continued growth driven by increased adoption of the iLet and its associated products, alongside ongoing investments in innovation and market expansion. The company remains focused on navigating regulatory challenges and optimizing its reimbursement strategies to enhance access to its products for patients with diabetes.